Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(31)
•••
Comment by stanleyon Dec 11, 2010 1:03pm
397 Views
Post# 17833759

What Is up with Brigus? HFT/Hot Potato Syndrome

What Is up with Brigus? HFT/Hot Potato SyndromeJosameyer:

[S] FINANCIALLY: What change/difference if any, has WD made since June 2010? ............

This is a thought to contemplate as the hedge and debt is addressed:

"At the end of the day you allocate money to those who knows what to do with it".

If Silver explodes due to (alleged) JPM activity will it take Gold along with it? Maybe, maybe not. Thus making the P2 & P3 of the BF Open Pit "extremely high grade". LOL

BWDIK? Who bot over 3.5 mln BRD over the past month? OT or CPP?

https://www.youtube.com/watch?v=Xs_rJLzf3Fw&NR=1

GLTAL - GLAP

Cheers
Stanley



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities